Optimal adaptive design in clinical drug development: a simulation example.

Optimal adaptive design in clinical drug development: a simulation example. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Optimal adaptive design in clinical drug development: a simulation example. Abstract Text:

Alan Maloney,Mats O Karlsson,Ulrika S H Simonsson,Alan Maloney,Mats O Karlsson,Ulrika S H Simonsson,

The objective of this article is to demonstrate optimal adaptive design as a methodology for improving the performance of phase II dose-response studies. Optimal adaptive design uses both information prior to the study and data accrued during the study to continuously update and refine the study design. Dose-response models include linear, log-linear, 4-parameter sigmoidal E(max), and exponential models. Where the response has both a placebo effect and plateau at higher doses, only the 4-parameter sigmoidal E(max) model behaves acceptably and hence is used to illustrate the methodology. Across 13 hypothetical dose-response scenarios considered, it was shown that the capability of the adaptive designs to "learn" the true dose response resulted in performances up to 180% more efficient than the best fixed optimal designs. This work exposes the common misconception that adaptive designs are somehow "risky." As shown in this simple simulation example, the converse is true. Adaptive designs perform extremely well both when prior information is accurate and inaccurate. This leads to improved dose-response models and dose selection in phase III. This benefits sponsors, regulators, and subjects alike by reducing sample size, increasing information, and providing better dose guidance.

Optimal adaptive design in clinical drug development: a simulation example. Publishing Authors By Initials

A Maloney,MO Karlsson,US Simonsson,A Maloney,MO Karlsson,US Simonsson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Optimal adaptive design in clinical drug development: a simulation example. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of clinical pharmacology

VOLUME: 47

Page Numbers: 1231-43

Journal Abbreviation:

ISSN: 0091-2700

DAY: 1

MONTH: Oct

YEAR: 2007

Optimal adaptive design in clinical drug development: a simulation example. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 366372

Optimal adaptive design in clinical drug development: a simulation example. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Optimal adaptive design in clinical drug development: a simulation example. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Optimal adaptive design in clinical drug development: a simulation example.

AFFILIATION: Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, University of Uppsala, Friggs Grand 4, Halmstad, Sweden. al.maloney@exprimo.com

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Optimal adaptive design in clinical drug development: a simulation example Related Publications

• A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.
• Acute effects of ipratropium bromide (ITBR, Sch 1000, Atrovent): a review of previous studies.
• Airway hyperreactivity. Definition and short review.
• Anatomical and pathophysiological considerations in aerosol therapy.
• Anticholinergic drugs--a review.
• Bronchial hyperreactivity.
• Bronchial reactivity in occupational asthma and bronchitis.
• Bronchial reactivity in relation to occupational bronchitis and asthma.
• Chronic cough and expectoration in patients with asthma and in patients with alpha1-antitrypsin deficiency.
• Clinical implications of bronchial hyperreactivity.
• Continuous and intermittent exposure to ethanol: effect on NG 108-15 cell membrane phospholipids.
• Evaluation of ethanol effects on PLC signal transduction pathways using cell lines of neuronal origin.
• Identification and characterization of an essential telomeric repeat binding factor in fission yeast.
• Method evaluation of Fusarium DNA extraction from mycelia and wheat for down-stream real-time PCR quantification and correlation to mycotoxin levels.
• Non-specific bronchial hyperreactivity: correlation to asthma and modifying factors.
• Optimal adaptive design in clinical drug development: a simulation example.
• Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.
• Pulmonary gas exchange at rest and during exercise in chronic bronchitis.
• Total nucleated cell differential for blood and bone marrow using a single tube in a five-color flow cytometer.
• Treatment of respiratory failure.